Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX Long-term Debt
Borrowings due after more than one year.
Gain Therapeutics, Inc.NASDAQ: GANX
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt falls 13.1% from a year ago
Long-term debt stood at $273.27K at the end of Q1 FY2026, down 13.1% from a year earlier and down 8.9% from the prior quarter. Over 3 fiscal years it compounded at -15.4% a year.
Context
- Long-term debt amounted to 1.5% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term debt keeps falling in the next quarterly balance sheet after a -13.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 300.08K USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- -15.6%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300.08K | -8.6% |
| FY2024 | 2024-12-31 | 328.33K | -26.9% |
| FY2023 | 2023-12-31 | 449.05K | -9.3% |
| FY2022 | 2022-12-31 | 495.26K | -16.1% |
| FY2021 | 2021-12-31 | 590.47K | — |
Long-term Debt vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's Mar 2026 long-term debt of $273.27K is the 4th highest of the 9 companies compared; the peer median is $14.91K.
- Its year-over-year change of -13.1% is the 3rd highest of 5, against a peer median of -16.6%.
- Long-term debt amounts to 1.5% of total assets for GANX, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $36.88M | -34.6% | -13.9% | 10.3% | |
| Mar 2026 | $32.65M | +1.5% | +3.6% | 16.2% | |
| Dec 2025 | $1.14M | +172.7% | -56.8% | 1.5% | |
| Mar 2026 | $273.27K | -13.1% | -15.4% | 1.5% | |
| Apr 2026 | $29.83K | -43.3% | -29.1% | 0.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
OSTXOS Therapies Incorporated | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GANX) | $14.91K | -16.6% | -21.5% | 0.2% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.88M | 7.31M | 11.79M | 10.39M | 20.84M |
| Short-term Investments | 0 | 12.83M | 5M | 0 | 0 |
| Net Receivables | 195.45K | 103.88K | 242.58K | 765.76K | 802.69K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 640.31K | 0 | 369.89K | 275.43K |
| Total Current Assets | 37.72M | 21.09M | 17.78M | 11.6M | 22.24M |
| Property, Plant & Equipment (Net) | 1.01M | 804.31K | 585.18K | 323.33K | 409.01K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 202.61K | 213.97K | 193.38K | 134.27K | 102.84K |
| Long-term Investments | 31.28K | 1.94M | 34.02K | 31.7K | 36.3K |
| Tax Assets | (31.28K) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 53.39K | 48.32K | 17.89K | 32.11K | 33.7K |
| Total Non-current Assets | 1.26M | 3.01M | 830.46K | 521.41K | 581.84K |
| Total Assets | 38.99M | 24.1M | 18.61M | 12.12M | 22.82M |
| Account Payables | 560.48K | 1.63M | 1.32M | 946.26K | 825.03K |
| Short-term Debt | 103.83K | 108.14K | 118.8K | 110.18K | 100.87K |
| Tax Payables | 380 | 107.31K | 48.97K | 0 | 0 |
| Deferred Revenue | 266.5K | 55.18K | 1.12M | 252.21K | 0 |
| Other Current Liabilities | 380 | 364.11K | 1.38M | 18.49K | 167.89K |
| Total Current Liabilities | 2.55M | 4.13M | 4.95M | 3.91M | 3.35M |
| Long-term Debt | 590.47K | 495.26K | 449.05K | 328.33K | 300.08K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 94.79K | 47.44K | 0 |
| Other Non-current Liabilities | 329.46K | 157.58K | 307.45K | 443.62K | 390.51K |
| Total Non-current Liabilities | 1.61M | 1.09M | 1.08M | 872.99K | 901.83K |
| Total Liabilities | 4.17M | 5.22M | 6.03M | 4.78M | 4.25M |
| Common Stock | 1.19K | 1.19K | 1.62K | 2.71K | 4.21K |
| Retained Earnings | (20.93M) | (38.52M) | (60.78M) | (81.19M) | (101.36M) |
| Accumulated OCI | (90.65K) | 35.63K | 247.24K | (247.55K) | 776.87K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 34.82M | 18.88M | 12.58M | 7.34M | 18.56M |
| Total Debt | 1.61M | 1.27M | 1.03M | 653.02K | 732.07K |
| Net Debt | (35.27M) | (6.04M) | (10.77M) | (9.73M) | (20.11M) |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.